Artificial intelligence based company Viz.ai, currently developing software for the detection of urgent stroke cases, has recently raised $21 million in venture capital to develop its portfolio.

The San Francisco and Tel Aviv Company received FDA clearance in February for its cloud computing platform named Viz LVO, which could analyze the brain scans for occlusions and send a notification to neurovascular specialists immediately.

Viz.ai also grabbed a second FDA clearance in April for CT perfusion analysis for its automated cerebral image processing software named Viz CTP.

Mamoon Hamid, the General Partner of Kleiner Perkins who merged the company’s board of directors said, “We were attracted not only to the technology behind Viz.ai and its impact on patient outcomes but also its adoption model; Many new health-tech solutions struggle to gain traction because they are an outside-in sale to medical teams, requiring changes to procedures and workflows. In contrast, physicians and their teams are driving adoption of the Viz.ai platform because it is not disruptive to emergency room procedures and fits naturally into existing systems.”

Viz.ai submitted its LVO to the FDA for detecting large vessel blockages. An alert notification will be sent to the specialist for an intervention if a blockage is detected.

Robert Ochs, Ph.D., the acting deputy director for radiological health from FDA said, "Strokes can cause serious and irreversible damage to patients; The software device could benefit patients by notifying a specialist earlier thereby decreasing the time to treatment. Faster treatment may lessen the extent or progression of a stroke.”